Could a diabetes drug boost fertility in PCOS? new trial tests combo therapy
NCT ID NCT07462065
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 4 trial tests whether adding pioglitazone (a diabetes drug) to standard clomiphene citrate improves ovarian stimulation and pregnancy rates in 62 infertile women with polycystic ovary syndrome (PCOS). Participants are randomly assigned to receive either pioglitazone or a placebo alongside clomiphene, and follicle growth is tracked via ultrasound. The study aims to see if the combination leads to more mature eggs and higher pregnancy rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
clomiphene citrate and pioglitazone
What this could lead to
If successful, this could show that adding pioglitazone to clomiphene improves ovarian stimulation and pregnancy rates in women with PCOS.
What could go wrong
This is a small Phase 4 trial with only 62 participants, so results may not apply to all women. Side effects like swelling, fluid retention, and weight gain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFERTILITY TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pakistan Atomic Energy Commission Hospital
RECRUITINGIslamabad, Federal, 44000, Pakistan
Contact Email: •••••@•••••